Clinical Trials Logo

Post-Menopausal Osteoporosis clinical trials

View clinical trials related to Post-Menopausal Osteoporosis.

Filter by:

NCT ID: NCT03432533 Recruiting - Clinical trials for Post-Menopausal Osteoporosis

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Start date: February 6, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

NCT ID: NCT02598934 Completed - Clinical trials for Post Menopausal Osteoporosis

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Start date: August 2004
Phase: Phase 4
Study type: Interventional

This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.

NCT ID: NCT02347865 Active, not recruiting - Clinical trials for Post Menopausal Osteoporosis

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

PILOTE
Start date: June 16, 2015
Phase: N/A
Study type: Observational

The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France

NCT ID: NCT01826656 Withdrawn - Clinical trials for Post-menopausal Osteoporosis

Bone Healing in Healthy and Post-menopausal Osteoporotic Women

Start date: May 2014
Phase: N/A
Study type: Interventional

Both the pathogenesis and the treatment of osteoporosis may potentially interfere at different levels on the multi-stage complex cascade of events involved in bone healing/regeneration. To our knowledge no human studies have been performed to clarify the potential effect of osteoporosis on post-extraction alveolar healing. The primary outcome of the study is to compare alveolar bone changes in width and height 3 months after tooth extraction in 10 post-menopausal osteoporotic women and 10 post menopausal non osteoporotic women by the use of cone-beam computer tomography (CBCT) images. The secondary outcomes considered are: clinical changes in the external contour of the ridge and periodontal parameters in the neighbouring teeth after a tooth extraction and 3 months later. In addition the accuracy of panoramic morphometric indexes in detecting osteoporosis will be measured.

NCT ID: NCT01732770 Completed - Clinical trials for Post Menopausal Osteoporosis

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Start date: November 2012
Phase: Phase 4
Study type: Interventional

This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.

NCT ID: NCT01674621 Completed - Clinical trials for Post Menopausal Osteoporosis

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Start date: August 2012
Phase: Phase 2
Study type: Interventional

To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to Transdermal Placebo and BA058 Injection for 6 months of treatment.

NCT ID: NCT01290094 Completed - Clinical trials for Post Menopausal Osteoporosis

A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Start date: April 2011
Phase: Phase 3
Study type: Interventional

This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.

NCT ID: NCT01232647 Recruiting - Clinical trials for Post-menopausal Osteoporosis

Vitamin K as Additive Treatment in Osteoporosis

VITKANDOP
Start date: April 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Vitamin K is thought to be important for bone health because it activates several proteins involved in bone formation. Poor dietary intake of vitamin K (mainly found in dark green leafy vegetables) is associated with bone loss and fractures. Giving supplements of the main dietary form of vitamin K (called K1) or another common form which our bodies make from K1(called MK4), to improve bone health have given mixed results. This confusion is thought to have arisen because these studies involved people who already had enough vitamin K or did not have osteoporosis. We want to test the hypothesis that treatment with bisphosphonates combined with vitamin K, in vitamin K deplete elderly women with osteoporosis, may offer additional benefit on skeletal metabolism and reduction of fracture risk. We want to test this by measuring vitamin K status in post-menopausal women with osteoporosis who are on the recommended treatment with a bisphosphonate and calcium/vitamin D supplements. Those with low vitamin K will then be recruited to study the effect of supplementation with either K1 or MK4.

NCT ID: NCT01224717 Completed - Clinical trials for Post-menopausal Osteoporosis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.

NCT ID: NCT00984893 Completed - Clinical trials for Post-Menopausal Osteoporosis

Intra-venous Zoledronic Acid Once Yearly

IVORY
Start date: November 2008
Phase: N/A
Study type: Observational

The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.